#South Korea #Seoul #Botulinum Toxin #SOLTOX #CELSET INC

CELSET Launches SOLTOX

On October 29, 2026, CELSET INC., a South Korean biotech firm specializing in medical aesthetics, announced the international launch of SOLTOX, its new brand of botulinum toxin type A. This strategic move positions SOLTOX within the rapidly growing medical aesthetics market and showcases the company's commitment to innovation and quality.

What is SOLTOX?

SOLTOX is available in two formulations: 100 units and 200 units. It is characterized by several unique technical features, including a 900 kDa molecular weight toxin complex, a lyophilized drug form, and an advanced purification process. These characteristics highlight CELSET's meticulous manufacturing approach, focusing on controlled processing, product characterization, and pharmaceutical quality.

The 900 kDa complex describes the molecular size of the botulinum toxin protein complex, including associated proteins. Importantly, this denotes a specific characteristic of the product but does not claim extended clinical effectiveness or higher potency. SOLTOX is delivered as a lyophilized powder that must be reconstituted prior to administration by qualified healthcare professionals in accordance with relevant product labeling and local regulations.

Advanced Purification Processes

Purification is also a pivotal aspect of SOLTOX's development. CELSET uses advanced technology to ensure the separation of the desired substance from undesired components during the botulinum toxin type A processing. The manufacturing process adheres to strict production conditions and quality control measures encompassing preparation, filling, lyophilization, and batch evaluation. CELSET emphasizes these manufacturing characteristics as the technical foundation of SOLTOX.

By launching SOLTOX, CELSET underscores the importance of composition identity and process control, avoiding confusion about manufacturing characteristics and unverified differences in patient outcomes. The brand's technical information is designed to be easily recognizable across the medical aesthetics industry, enhancing its market presence.

International Presence and Future Outlook

The introduction of SOLTOX marks a significant milestone in CELSET’s international activities in the medical aesthetics sector. This launch reflects the increasing visibility of Korean biotechnology and manufacturing within the aesthetic medicine landscape and recognizes the importance of established medical channels and regulatory frameworks specific to each market.

CELSET sees the development of market opportunities at the country level and professional relationships as integral to SOLTOX’s international presence. This brand extension enriches CELSET's portfolio in aesthetic medicine, complementing its focus on scientifically-backed communications about its products. The company stresses the importance of coherent brand presentation and clear information for healthcare professionals across diverse markets, ensuring that SOLTOX adheres to individual countries' regulatory requirements.

About CELSET INC.

Situated in Seoul, South Korea, CELSET INC. is a biotech firm dedicated to the medical aesthetics sector. SOLTOX symbolizes the company's commitment to unique brands, manufacturing principles in aesthetic medicine, and professional communication for the global aesthetic industry. For inquiries, visit their official site at celset-aesthetics.com.